GLP1R and type 2 diabetes mellitus: Many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve cardiovascular outcomes [12] and albuminuria-based kidney endpoints [13–15] in patients with type 2 diabetes at high cardiovascular risk.